Moderna’s new vaccine works better on the immune system

Moderna says their latest Covid-19 vaccine is showing signs a stronger immune response against the virus than the shot currently offered – and longer shelf life.

The third phase of the study involved roughly 11,400 people aged 12 and older across the United States, United Kingdom and Canada. The new shot revealed a better immune response against omicron subvariants BA.4 and BA.5 and the original strain of the virus. With a better vaccination rate in comparison with a vaccine targeting the same variants, the advantages were clear in patients over 65, who’re at highest risk of developing health conditions from Covid.

With their current Spikevax vaccine the just one available on the market, this winning news comes as Moderna continues on a competitive path with rival Pfizer to share more of the vaccine market. They are also attempting to diversify revenue sources after a pointy drop in demand for Covid products last yr.

The new shot is designed to last more in the refrigerator, making it easier to distribute around the world, especially in countries with limited freezing facilities. Another key element of the new vaccine is a mix of a vaccine that may fight Covid-19 and influenza. Both rival drug corporations have said the one-time virus protection is a “convenience” and an incentive for more people to get vaccinated.

However, the excellent news doesn’t appear to impress investors. , wrestling Moderna fell almost 3% during afternoon trading on March 26, contributing to a 28% decline over the past 12 months. Surprisingly, the company managed to report profit of $217 million in the fourth quarter, but that did not prevent Moderna’s current product from declining over the past yr. During the fall 2023 Covid-19 season, Moderna grew to 48% market share in the US in comparison with 37% in 2022.

That doesn’t stop Moderna from continuing to fight disease. They are reportedly working on a shot that may fight the flu, cancer and more. Their vaccine against respiratory syncytial virus – or RSV – is anticipated to receive Food and Drug Administration (FDA) approval by May 2024.

Following its initial announcement at its annual research and development day in September 2023, Moderna outlined plans so as to add 15 products to its lineup over the next five years.